Contact RX Tesa

Reach the editors

RX Tesa is an editorial publication, and this form reaches the editors who maintain the tesamorelin summaries. The most useful messages point to a specific figure or citation — if a study has been superseded, a PubMed link has rotted, or a number on a page does not match its source, tell us which page and which claim and we will check it against the literature.

We read every message about accuracy. We update the record when the published evidence warrants it, and we log corrections rather than quietly overwriting them. New tesamorelin research appears regularly — the 2026 meta-analysis is the most recent entry in our reference list — and pointers to trials or analyses we have not yet folded in are genuinely welcome. The aim is a record that stays current with the published science, not a page frozen at its launch date.

What we cannot answer

We cannot give medical advice, interpret your lab results, recommend a dose, or tell you whether tesamorelin is appropriate for you. Those are questions for a licensed clinician who knows your history — not for an editorial site. We also do not sell, source, supply, or refer anyone to suppliers of tesamorelin or any other compound; messages asking where to obtain it will not receive a sourcing reply.

This boundary is not a formality. Tesamorelin is a prescription drug approved for one narrow indication, and the off-label questions people most want answered — will it work for general fat loss, is it safe to run long-term, what dose should I use — are precisely the ones the published evidence does not settle and we are not positioned to answer. We would rather say so directly than improvise.

For anything about the studies themselves — what a trial measured, where a figure came from, how to read a pharmacokinetic result — we are glad to help, and the full reference list is the place those answers ultimately point.